Notice2023-24551
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
November 7, 2023
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 214 (Tuesday, November 7, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 214 (Tuesday, November 7, 2023)]
[Notices]
[Page 76836]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-24551]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Amy F. Petrik, Ph.D. at 240-627-3721
or <a href="/cdn-cgi/l/email-protection#2849455106584d5c5a414368464140064f475e"><span class="__cf_email__" data-cfemail="33525e4a1d435647415a58735d5a5b1d545c45">[email protected]</span></a>. Licensing information may be obtained by
communicating with the indicated licensing contact at the Technology
Transfer and Intellectual Property Office, National Institute of
Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD,
20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement
will be required to receive copies of unpublished information related
to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Base-Covered HIV-1 Envelope Ectodomains and Their Use
Description of Technology: Researchers at the Vaccine Research
Center (``VRC'') of the National Institute of Allergy and Infectious
Diseases (``NAID'') continue to pursue a safe and effective HIV-1
vaccine to combat the HIV-1/AIDS pandemic.
To this end, researchers have engineered the soluble HIV-1
ectodomain trimer so that it is stabilized in its prefusion
conformation by artificial disulfides, helix-disrupting prolines, and
other structure-based alterations. However, mice and non-human primates
immunized with these engineered soluble HIV-1 trimers produced a
significant (>90% in some cases) immune response to the exposed trimer
base.
VRC researchers further modified the engineered prefusion soluble
HIV-1 trimers by adding N-linked glycans to specific sites on the
protein's base to block this immunodominant surface. They found that
these N-linked glycans did reduce production of non-neutralizing
antibodies directed to the trimer base. These soluble, glycan-masked
prefusion HIV-1 trimers are envisioned as being a part of a
heterologous prime-boost vaccine regimen.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as further development and evaluation under a research
collaboration.
Potential Commercial Applications:
<bullet> Vaccine for prevention of HIV-1 infection
<bullet> Therapeutic vaccine for treatment of HIV-1 infection
Competitive Advantages:
<bullet> Currently, no licensed HIV vaccine exists
Development Stage:
<bullet> Animal studies
Inventors: Peter Kwong, John Mascola, Tongqing Zhou, Adam Olia,
Reda Rawi, Yongping Yang, Cheng Cheng (all of NIAID).
Publications: Olia, et al. (2023) Soluble prefusion-closed HIV-
envelope trimers with glycan-covered bases. iScience 26, 107403, August
18, 2023. DOI: <a href="https://doi.org/10.1016/j.sci.2023.107403">https://doi.org/10.1016/j.sci.2023.107403</a>.
Intellectual Property: HHS Reference Number E-079-2022 includes PCT
Patent Application No. PCT/US2023/065009 filed on March 27, 2023.
Licensing Contact: To license this technology, please contact Amy
F. Petrik, Ph.D., 240-627-3721; <a href="/cdn-cgi/l/email-protection#8feee2f6a1ffeafbfde6e4cfe1e6e7a1e8e0f9"><span class="__cf_email__" data-cfemail="1879756136687d6c6a717358767170367f776e">[email protected]</span></a>, and reference E-
079-2022.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2023-24551 Filed 11-6-23; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on November 7, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.